550
Participants
Start Date
July 31, 2006
Primary Completion Date
July 31, 2010
Study Completion Date
July 31, 2010
Etanercept
10 mg twice weekly, subcutaneous injection for 52 weeks
Etanercept
25 mg, twice weekly, subcutaneous injection for 52 weeks
Methotrexate
up to 8 mg per week, oral dosing for 52 weeks
Pfizer Investigational Site, Ōta-ku
Pfizer Investigational Site, Kawasaki
Pfizer Investigational Site, Yokohama
Pfizer Investigational Site, Nagoya
Pfizer Investigational Site, Kakogawa
Pfizer Investigational Site, Hiroshima
Pfizer Investigational Site, Munakata
Pfizer Investigational Site, Fukuoka
Pfizer Investigational Site, Kurume
Pfizer Investigational Site, Kumamoto
Pfizer Investigational Site, Miyazaki
Pfizer Investigational Site, Hyūga
Pfizer Investigational Site, Kagoshima
Pfizer Investigational Site, Fukui-shi
Pfizer Investigational Site, Toyama
Pfizer Investigational Site, Miyagi
Pfizer Investigational Site, Sendai
Pfizer Investigational Site, Nagoya
Pfizer Investigational Site, Goshogawara
Pfizer Investigational Site, Asahi
Pfizer Investigational Site, Matsuyama
Pfizer Investigational Site, Fukuoka
Pfizer Investigational Site, Fukuoka
Pfizer Investigational Site, Iizuka
Pfizer Investigational Site, Kurume
Pfizer Investigational Site, Takasaki
Pfizer Investigational Site, Asahikawa
Pfizer Investigational Site, Sapporo
Pfizer Investigational Site, Katoh
Pfizer Investigational Site, Yūki
Pfizer Investigational Site, Komatsu
Pfizer Investigational Site, Kagoshima
Pfizer Investigational Site, Sagamihara
Pfizer Investigational Site, Kumamoto
Pfizer Investigational Site, Sasebo
Pfizer Investigational Site, Ikoma
Pfizer Investigational Site, Kawagoe
Pfizer Investigational Site, Tokorozawa
Pfizer Investigational Site, Bunkyo-ku
Pfizer Investigational Site, Sumida-ku
Pfizer Investigational Site, Kato City Fujita Letter Higashiyama
Lead Sponsor
Pfizer
INDUSTRY